Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding

  1. Paul Chappell
  2. El Kahina Meziane
  3. Michael Harrison
  4. Łukasz Magiera
  5. Clemens Hermann
  6. Laura Mears
  7. Antony G Wrobel
  8. Charlotte Durant
  9. Lise Lotte Nielsen
  10. Soren Buus
  11. Nicola Ternette
  12. William Mwangi
  13. Colin Butter
  14. Venugopal Nair
  15. Trudy Ahyee
  16. Richard Duggleby
  17. Alejandro Madrigal
  18. Pietro Roversi
  19. Susan M Lea
  20. Jim Kaufman  Is a corresponding author
  1. University of Oxford, United Kingdom
  2. University of Cambridge, United Kingdom
  3. University of Copenhagen, Denmark
  4. Pirbright Institute, United Kingdom
  5. The Royal Free Hospital, United Kingdom

Abstract

Highly polymorphic MHC molecules are at the heart of adaptive immune responses, playing crucial roles in many kinds of disease and in vaccination. We report that breadth of peptide presentation and level of cell surface expression of class I molecules are inversely correlated in both chickens and humans. This relationship correlates with protective responses against infectious pathogens including Marek's disease virus leading to lethal tumours in chickens and HIV infection progressing to AIDS in humans. We propose that differences in peptide binding repertoire define two groups of MHC class I molecules strategically evolved as generalists and specialists for different modes of pathogen resistance. We suggest that differences in cell surface expression level ensure the development of optimal peripheral T cell responses. The inverse relationship of peptide repertoire and expression is evidently a fundamental property of MHC molecules, with ramifications extending beyond immunology and medicine to evolutionary biology and conservation.

Article and author information

Author details

  1. Paul Chappell

    Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. El Kahina Meziane

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Michael Harrison

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Łukasz Magiera

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Clemens Hermann

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Laura Mears

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Antony G Wrobel

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Charlotte Durant

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Lise Lotte Nielsen

    Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  10. Soren Buus

    Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    The authors declare that no competing interests exist.
  11. Nicola Ternette

    Target Discovery Institute, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. William Mwangi

    Pirbright Institute, Compton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Colin Butter

    Pirbright Institute, Compton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Venugopal Nair

    Pirbright Institute, Compton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Trudy Ahyee

    Anthony Nolan Research Institute, The Royal Free Hospital, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Richard Duggleby

    Anthony Nolan Research Institute, The Royal Free Hospital, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Alejandro Madrigal

    Anthony Nolan Research Institute, The Royal Free Hospital, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. Pietro Roversi

    Department of Biochemistry, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Susan M Lea

    Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Jim Kaufman

    Department of Pathology, University of Cambridge, Cambridge, United Kingdom
    For correspondence
    jfk31@cam.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All procedures involving chickens were carried out at the University of Cambridge under Home Office project license PPL 80/2420 and with ethical approval of the Local Ethical Review Committee.

Human subjects: Anthony Nolan registrants signed written consent forms, with all procedures carried out under Human Tissue Act licensing number 22513 and with approval of the local Research Ethics committee (REC).

Copyright

© 2015, Chappell et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,450
    views
  • 943
    downloads
  • 109
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paul Chappell
  2. El Kahina Meziane
  3. Michael Harrison
  4. Łukasz Magiera
  5. Clemens Hermann
  6. Laura Mears
  7. Antony G Wrobel
  8. Charlotte Durant
  9. Lise Lotte Nielsen
  10. Soren Buus
  11. Nicola Ternette
  12. William Mwangi
  13. Colin Butter
  14. Venugopal Nair
  15. Trudy Ahyee
  16. Richard Duggleby
  17. Alejandro Madrigal
  18. Pietro Roversi
  19. Susan M Lea
  20. Jim Kaufman
(2015)
Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding
eLife 4:e05345.
https://doi.org/10.7554/eLife.05345

Share this article

https://doi.org/10.7554/eLife.05345

Further reading

    1. Immunology and Inflammation
    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Patsy R Tomlinson, Rachel G Knox ... Robert K Semple
    Research Article

    PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.